
浏览全部资源
扫码关注微信
大理大学 药学与化学学院,实验室管理处,云南 大理 671000
李银蕊,在读硕士,从事抗肿瘤药理学研究,E-mail:18760968074@163.com
吴定宇,硕士,讲师,从事实验动物学研究,Tel:0872-2250289,E-mail:fetoio@sina.com
收稿日期:2020-07-04,
网络出版日期:2020-11-06,
纸质出版日期:2021-03-05
移动端阅览
李银蕊,吕鸿,彭芳等.美洲大蠊多肽PAE2逆转肝癌多药耐药性[J].中国实验方剂学杂志,2021,27(05):52-61.
LI Yin-rui,LYU Hong,PENG Fang,et al.Study on Periplaneta americana Polypeptide PAE2 in Reversing Multidrug Resistance for Liver Cancer[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(05):52-61.
李银蕊,吕鸿,彭芳等.美洲大蠊多肽PAE2逆转肝癌多药耐药性[J].中国实验方剂学杂志,2021,27(05):52-61. DOI: 10.13422/j.cnki.syfjx.20212523.
LI Yin-rui,LYU Hong,PENG Fang,et al.Study on Periplaneta americana Polypeptide PAE2 in Reversing Multidrug Resistance for Liver Cancer[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(05):52-61. DOI: 10.13422/j.cnki.syfjx.20212523.
目的
2
探讨美洲大蠊多肽PAE
2
体内逆转肝癌多药耐药(MDR)的作用及机制。
方法
2
采用Balb/c-nude小鼠腋下接种HepG2和HepG2/ADM细胞分别建立肝癌敏感株动物模型和肝癌MDR动物模型,模型制备成功后,将裸鼠随机分为正常组,HepG2模型组,HepG2/ADM模型组,索拉菲尼组[30 mg·kg
-1
,灌胃(
ig
)],HepG2/ADM+PAE
2
[静脉注射(
iv
)]低、中、高剂量组(50,100,200 mg·kg
-1
),HepG2/ADM+PAE
2
ig
低、中、高剂量组(50,100,200 mg·kg
-1
),脱脂膏组(200 mg·kg
-1
,
ig
),美洲大蠊前期粗提物CⅡ-3组(200 mg·kg
-1
,
ig
),每2日测量1次裸鼠体质量及肿瘤体积,并记录,末次给药后,次日取裸鼠肿瘤组织,记录瘤质量,采用免疫组织化学(IHC)和实时荧光定量聚合酶链式反应(Real-time PCR)测定美洲大蠊多肽PAE
2
对肿瘤组织中P糖蛋白(P-gp),肺耐药相关蛋白(LRP),乳腺癌耐药蛋白(BCRP),蛋白激酶C(PKC),谷胱甘肽巯基转移酶-
π
(GST-
π
),拓扑异构酶Ⅱ(ToPoⅡ),MDR基因1(MDR1)及MDR相关蛋白1(MRP1)蛋白水平和基因水平表达的影响。另同时设置口服和静脉2种给药组别以研究美洲大蠊PAE
2
的基本药代动力学特征。
结果
2
裸小鼠体质量方面,造模成功后,与正常组比较,裸小鼠体质量明显减轻(
P
<
0.05),经各药物治疗后,体质量有一定回升,但仍然不及正常裸小鼠。抑瘤作用方面,与模型组比较,美洲大蠊多肽PAE
2
iv
组中剂量组抑瘤效果最好(
P
<
0.05),口服给药组抑瘤作用随剂量的增加而增加,高剂量组效果最好(
P
<
0.05),美洲大蠊前期粗提物CⅡ-3无明显抑瘤作用,脱脂膏具有一定的抑瘤效果(
P
<
0.05)。MDR相关蛋白和酶方面,美洲大蠊多肽PAE
2
在体内对MDR相关的蛋白和酶均有一定影响,主要可能通过抑制肿瘤组织内LRP,BCRP表达和不同程度影响上述相关蛋白、基因表达而抑制细胞内药物外排,从而促进肿瘤凋亡,且作用优于美洲大蠊前期粗提物CⅡ-3和脱脂膏。
结论
2
美洲大蠊多肽PAE
2
可能通过影响介导MDR的相关蛋白和酶的表达,减少药物外排,促进细胞内药物累积、细胞凋亡,从而发挥逆转HepG2/ADM细胞Balb/c-nude小鼠移植瘤MDR的作用。
Objective
2
To investigate the effect and mechanism of PAE
2
, a polypeptide of
Periplaneta americana,
in reversing multidrug resistance (MDR) for liver cancer
in vivo
.
Method
2
Balb/c-nude mice were inoculated with HepG2 and HepG2/ADM cells under the armpits to establish animal models of liver cancer sensitive strains and animal models of MDR respectively. After successful modeling, the nude mice were randomly divided into normal group, HepG2 model group, HepG2/ADM model group, sorafenib group (positive drug control group,
ig
30 mg·kg
-1
), HepG2/ADM+PAE
2
(
iv
) low, medium and high dose groups (50, 100, 200 mg·kg
-1
), HepG2/ADM+PAE
2
(
ig
) low, medium, and high dose groups (50, 100, 200 mg·kg
-1
), skim cream group (
ig
200 mg·kg
-1
), and CⅡ-3 group (
ig
200 mg·kg
-1
), all of which received corresponding drug treatment. The body weight and tumor volume of nude mice were measured and recorded every 2 days. The next day after the last administration, tumor tissues of nude mice were taken to record the tumor weight. The effect of
P. americana
polypeptide PAE
2
on permeability-glycoprotein(P-gp), lung resistance protein(LRP) , breast cancer resistance protein(BCRP), protein kinase C(PKC), glutathione S-transferase-π(GST-π), topo-isomerase typeⅡ(ToPoⅡ), multidurg resistance gene 1(MDR1)
and Multidrug resistance-associated proteins(MRP1) of the protein level and gene level expression in tumor tissues were determined by immunohistochemistry (IHC) and real-time quantitative polymerase chain reaction (Real-time PCR). In addition, both oral and intravenous administration groups were set up at the same time for preliminary study on the basic pharmacokinetic characteristics of
P. americana
polypeptide PAE
2
.
Result
2
After the successful modeling, the body weight of the nude mice was significantly lower than that in the normal mice(
P
<
0.05). After treatment with corresponding drugs, the body weight increased to a certain extent, but it was still not as good as the normal nude mice. In
iv
administration, the medium-dose
P. americana
polypeptide PAE
2
showed the best anti-tumor effect as compared with the model group (
P
<
0.05), while in oral administration, the anti-effect increased with the increase of the dose, so the high-dose group showed the best effect (
P
<
0.05). Preliminary crude extract CII-3 had no obvious anti-tumor effect, and skim cream showed a certain anti-tumor effect (
P
<
0.05).
P. americana
polypeptide PAE
2
had certain effects on MDR related proteins and enzymes
in vivo
, mainly by inhibiting the expression of LRP and BCRP in tumor tissues and affecting the expression of these related proteins and genes to different degrees to inhibit intracellular drugs outflow, thereby promoting tumor apoptosis, and the effect was superior to that of the
P. americana
crude extract CⅡ-3 and skim cream.
Conclusion
2
P. americana
polypeptide PAE
2
may reduce the drug efflux, promote intracellular drug accumulation and apoptosis by affecting the expression of related proteins and enzymes that mediate multidrug resistance, thereby exerting a reverse effect on HepG2/ADM cells Balb/c MDR in nude mice.
原发性肝癌诊疗规范( 2019 年 版)编写专家委员会.原发性肝癌诊疗规范(2019年版) [J]. 中国临床医学 , 2020 , 27 ( 1 ): 140 - 160 .
EGGERT T , GRETEN T F . Current standard and future perspectives in non-surgical therapy for hepatocellular carcinoma [J]. Digestion , 2017 , 96 ( 1 ): 1 - 4 .
LING S , LI J , SHAN Q , et al . USP22 mediates the multidrug resistance of hepatocellular carcinoma via theSIRT1/AKT/MRP1 signaling pathway [J]. Mol Oncol , 2017 , 11 ( 6 ): 682 - 695 .
LOU J S , YAO P , TISM K W K . Cancer treatment by using traditional Chinese medicine:probing active compounds in anti- multidrug resistance during drug therapy [J]. Curr Med Chem , 2018 , 25 ( 38 ): 5128 - 5141 .
神农本草经 [M]. 吴普 , 述 . 孙星衍,孙冯翼,辑 . 北京 : 商务印书馆 , 1955 : 90 .
张蕊 , 袁发璐 , 李婷 , 等 . 美洲大蠊提取物对人肝癌HepG2细胞的作用机制研究 [J]. 中国现代医学杂志 , 2017 , 27 ( 12 ): 1 - 8 .
王瑶 , 李婷 , 乔婷婷 , 等 . 美洲大蠊提取物逆转BEL-7402/5-Fu多药耐药性的作用及机制研究 [J]. 药学研究 , 2017 , 36 ( 6 ): 315 - 318 .
金家瑞 , 郭美仙 , 张冰清 , 等 . 美洲大蠊抗肿瘤组分CⅡ-3在肿瘤化疗中的增效减毒作用研究 [J]. 动物医学进展 , 2018 , 39 ( 12 ): 147 - 152 .
李娇 , 郭美仙 , 张冰清 , 等 . 美洲大蠊提取物CⅡ-3对肝癌H22荷瘤小鼠作用研究 [J]. 中华肿瘤防治杂志 , 2017 , 24 ( 11 ): 739 - 744 .
刘俊勇 , 夏盟恺 , 彭芳 . 美洲大蠊提取物逆转肝癌耐药性的实验研究 [J]. 中国生化药物杂志 , 2015 , 35 ( 4 ): 19 - 23 .
乔婷婷 , 牛春丽 , 彭芳 . 美洲大蠊逆转肝癌多药耐药性的研究 [J]. 中国生化药物杂志 , 2015 , 35 ( 4 ): 35 - 38 .
李洪文 , 耿玲 , 刘光明 , 等 . 美洲大蠊脱脂膏及其活性炭脱色物体外抗菌活性研究 [J]. 中国实验方剂学杂志 , 2012 , 18 ( 11 ): 159 - 161 .
普小菲 , 罗亦佳 , 彭丽 , 等 . 美洲大蠊提取物CⅡ-3体内外抗HSV-2实验研究 [J]. 大理学院学报 , 2014 , 13 ( 10 ): 5 - 9 .
何晓晓 , 熊枝繁 , 邱梦君 , 等 . 阿帕替尼对人肝癌裸鼠皮下移植瘤生长及生物钟基因表达的影响 [J]. 山东医药 , 2018 , 58 ( 8 ): 31 - 33 .
张萌 , 彭利 , 乔治斌 , 等 . 罗格列酮对人肝癌细胞HepG2裸鼠移植瘤的影响及机制 [J]. 中国老年学杂志 , 2015 , 35 ( 8 ): 2191 - 2194 .
陈俊雅 , 耿玲 , 张旭强 , 等 . 美洲大蠊提取物CⅡ-3对H22肝癌小鼠血管生成作用的研究 [J]. 肿瘤学杂志 , 2012 , 18 ( 4 ): 274 - 276 .
陈宝安 , 郭青龙 . 恶性肿瘤多药耐药的逆转 [M]. 南京 : 东南大学出版社 , 2013 : 29 - 30 .
周际 . 实用肿瘤内科学 [M]. 2版 . 北京 : 人民卫生出版社 , 1999 : 94 - 97 .
WU Q , YANG Z , NIE Y , et al . Multi-drug resistance in cancer che- motherapeutics:mechanisms and lab approaches [J]. Cancer Lett , 2014 , 347 ( 2 ): 159 - 166 .
余云霞 , 夏嘉文 , 熊友香 . 中药逆转肝癌多药耐药机制的研究进展 [J]. 上海中医药杂志 , 2019 , 53 ( 8 ): 92 - 97 .
喻喆 , 吴涛 , 张阳 . 槐耳清膏体外逆转人肝癌耐药细胞BEL-7402/5-Fu多药耐药性 [J]. 肿瘤学杂志 , 2013 , 19 ( 6 ): 443 - 447 .
LEDWITCH K V , ROBERTS A G . Cardiovascular ion channel inhibitor drug-drug interactions with P-glycoprotein [J]. AAPS J , 2017 , 19 ( 2 ): 409 - 420 .
TANDIA M , MHIRI A , PAULE B , et al . Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2):monocentric study [J]. Cancer Chemother Pharmacol , 2017 , 79 ( 4 ): 759 - 766 .
王亚琪 , 曾普华 , 郜文辉 , 等 . 益气化瘀解毒方对MRP、GST- π 和Topo Ⅱ基因在Sorafenib获得性耐药人肝癌QGY7702细胞表达的干预研究 [J]. 吉林中医药 , 2020 , 40 ( 4 ): 505 - 509 .
于树娜 , 蒋吉英 , 赵世福 , 等 . LRP、GST- π 在肝细胞癌中的表达及意义 [J]. 现代肿瘤医学 , 2010 , 18 ( 1 ): 102 - 105 .
万仁瑞 . ABCG2、LRP在索拉非尼耐药的原发性肝癌的表达及临床意义 [D]. 郑州 : 郑州大学 , 2016 .
张亮 , 隋成旭 , 宋磊 . 肝癌组织中p-gp170、GST- π 、TopoⅡ蛋白的表达 [J]. 肿瘤基础与临床 , 2014 , 27 ( 6 ): 472 - 476 .
王雷 , 王煜霞 , 陈丽平 , 等 . P-gp,MRP,LRP和GST-π等多药耐药蛋白在肝癌中的协同表达研究 [J]. 河南师范大学学报:自然科学版 , 2015 , 43 ( 4 ): 134 - 137 .
王雷 , 王煜霞 , 陈丽平 , 等 . 原发性肝癌中多药耐药蛋白谷胱甘肽转移酶及拓扑异构酶Ⅱ的表达与临床病理指标的相关性 [J]. 新乡医学院学报 , 2015 , 32 ( 7 ): 626 - 628 .
邓薇 . Ca 2+ 对人肝癌多药耐药细胞PKC的诱导作用 [D]. 武汉 : 湖北中医药大学 , 2012 .
0
浏览量
20
下载量
3
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621